Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2012 Feb;27(1):41–55. doi: 10.1089/cbr.2011.1097

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright 2012, Mary Ann Liebert, Inc.

PMC Copyright notice

FIG. 5. — Influence of covalent bonding epirubicin to anti-HER2/neu monoclonal immunoglobulin based on the cytotoxic anti-neoplastic potency of epirubicin compared to epirubicin-(C₃-amide)-[anti-HER2/neu] synthesized utilizing a UV-photoactivated epirubicin-(C₃-amide) intermediate. (▪) covalent epirubicin-(C₃-amide)-[anti-HER2/neu] immunochemotherapeutic, and (♦) epirubicin chemotherapeutic. Mammary adenocarcinoma SKBr-3 monolayer populations were incubated with epirubicin or covalent epirubicin-(C₃-amide)-[anti-HER2/neu] immunochemotherapeutic for 72 hours and cytotoxic anti-neoplastic potency measured as a function of MTT cell vitality stain intensity relative to matched negative reference controls. MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide.